Original article from CBS Boston by Lisa Hughes. January 9, 2018 BOSTON (CBS)...
The BU Annual Fund Leadership Giving Society presents a conversation with Dr. Ronald Corley, professor and chair of the microbiology at the BU School of Medicine and director of the National Emerging Infectious Diseases Laboratories (NEIDL).
Original article from Boston 25 News. May 30, 2017
BOSTON – A lab to study deadly diseases like Ebola and bubonic plague is just one vote away from approval in the heart of Boston. Supporters say it will speed the development of new vaccines and cures. But after 15 year of fighting, the neighborhood that’s home to the lab is making a final push to keep the diseases away from the busy urban hub.
“It’s the environment. When you open up your window, you see what we’re smelling. That’s what they’re smelling in their house,” said Roxbury activist Klare Allen.
Allen has been fighting for decades to keep her neighborhood safe, and says she’s seen record high asthma rates among the children and cancer rate in adults. She made it a personal mission to stop a level 4 Biosafety lab from operating in Boston’s South End.
Boston University received a $200 million federal grant in 2003 to build the regional lab. The goal was to study deadly diseases. But critics say contaminants could spread region-wide when research material is transferred between labs.
A campaign issue for local leaders
Roxbury City Councilor and Boston mayoral candidate Tito Jackson is making the Biolab one of his campaign issues, saying the area is tired of being a dumping ground.
“There are at least two trash transfer stations. There’s also a highway. There’s a jail. In addition there’s three methadone clinics. It’s not a ‘not in my backyard’, but it can’t all be in the backyard of that neighborhood,” said Jackson.
Boston University maintains, residents will be safe, and conducts tours like to anyone who requests them.
In a statement B.U. told Boston 25: “The issues you raise have all been addressed many times over the past decade by independent panels of scientists; by federal, state and city agencies; and by a federal and state court. In every case the conclusion is that the lab can be operated safely in its location.”
Original article from WCAI by Heather Goldstone May 22, 2017
Ebola is back. The virus killed more than 11,000 people between 2014 and 2016. It was the largest Ebola outbreak ever documented. Now, health officials say there’s a new outbreak in the Democratic Republic of Congo.
Officials are reporting four deaths and more than thirty suspected cases of Ebola in the past two weeks. They are also monitoring more than 400 individuals who came into contact with those patients. Still, because the area is so remote, officials say the risk of the outbreak spreading beyond national borders is low to medium.
On the other hand, the lack of road access and electricity in the region is a significant challenge for those treating patients and trying to contain the outbreak. WHO is preparing for the possibility of using a vaccine that was put into experimental use during the 2014-2016 West Africa outbreak. At that time, there were ethical questions about using a relatively untested vaccine in humans. Now, it’s more a question of logistics.
“This vaccine is still in development,” said John Conner, Associate Professor of Microbiology at Boston University School of Medicine and the National Emerging Infectious Diseases Laboratory. “This is not a vaccine that comes in a freeze-dried formula that can sit on somebody’s shelf for five years until it’s needed and then deployed instantaneously.”
Original article in Time Health Magazine – Alexandra Sifferlin May 03, 2017
The Ebola outbreak of 2014 infected more than 28,000 people in West Africa and killed more than 11,000. It also exposed gaps in the world’s ability to respond to epidemics of infectious diseases.
Are we more prepared now to respond to future emerging disease outbreaks? Experts say countries are better positioned, but there’s still a lot of room for improvement. “[Ours] is not a culture of outbreak prevention,” said Dr. Nahid Bhadelia, medical director of the Special Pathogen Unit at the Boston University School of Medicine, during a panel at Fortune’s Brainstorm Health Conference on Wednesday. Bhadelia worked as an Ebola treatment unit clinician on four different trips to West Africa during the outbreak. “We chase one pathogen after another.”
For more, visit Time Health http://time.com/4765674/ebola-pandemic-prevention/
Original article from: Scientific American posted on April 12, 2017. by Helen Branswell
But the trials process was too slow, and in the end, a massive influx of outside medical help and strict enforcement of measures to prevent ongoing infection were what brought the outbreak under control.
Now, a new report commissioned by the National Academies of Sciences, Engineering, and Medicine attempts to chart a road map for expedited clinical trials for future epidemics, hoping to ensure that the lessons from the devastating Ebola outbreak are not forgotten.
“There will be one. The more we can start now, the better we’ll be,” said Dr. Gerald Keusch, co-chairman of the committee that produced the report.
The report, “Integrating Clinical Research into Epidemic Response: The Ebola Experience,” was released Wednesday.
A number of the recommendations in the nearly 300-page report focus on trying to build up health systems in low-income countries, so that they are better able to spot, respond to, and contribute to research during future disease outbreaks.
Original article from: BU Today posted on March 7, 2017. by Art Jahnke
Infectious disease experts and administrators from Boston University told the Boston Biosafety Committee (BBC) on Monday night that the ability to conduct research at Biosafety Level 4 (BSL-4) at BU’s National Emerging Infectious Diseases Laboratory (NEIDL) would speed the development of treatments and vaccines for life-threatening diseases and further the development of Boston as the country’s most vital hub of biomedical research. The BBC, made up of biosafety experts and community residents, is an advisory group to the Boston Public Health Commission (BPHC), whose approval of BSL-4 research, currently sought by the NEIDL, is the final regulatory step required for the laboratory to conduct such research. In December, after more than two years of intensive review, the Centers for Disease Control and Prevention (CDC) approved BSL-4 research at the NEIDL, which has been conducting research at BSL-2 and BSL-3.
Monday night’s public meeting of the BBC, which was devoted to discussion of NEIDL’s request for permission to conduct BSL-4 research, opened with a lengthy review of training practices and other safety precautions that have been established at the laboratory. Situated on BU’s Medical Campus in the South End, the NEIDL has been the focus of years of litigation and controversy, with opponents arguing that its urban location introduces a large population to unnecessary risk, and proponents contending that the Medical Campus site is essential to attract top research talent and foster the necessary interdisciplinary research collaboration. Completed in 2008, the lab meets the most stringent safety specifications set by the United States government for conducting infectious disease research. There are currently 11 BSL-4 labs across North America—10 in the United States and one in Winnipeg, Canada.
Original article from: BU Today posted on March 6, 2017. by Sara Rimer
The Boston Public Health Commission will hold a public meeting this evening, Monday, March 6, to discuss a request by Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) for permission to conduct research at Biosafety Level 4 (BSL-4). The meeting will be held in the Hayes Conference Room on the second floor of 1010 Massachusetts Avenue from 5 to 7:30 p.m.
After more than two years of intensive review, BSL-4 research at the NEIDL was approved by the Centers for Disease Control and Prevention (CDC) in December, bringing NEIDL scientists closer to finding new ways to prevent and treat Ebola and other dangerous pathogens. The lab, on BU’s Medical Campus in the South End, was built according to the most stringent safety specifications set by the US government for conducting infectious disease research. It still needs approval from the Boston Public Health Commission before scientists can conduct research at BSL-4.
The NEIDL, which has been conducting research at BSL-2 and BSL-3, is part of a national network of secure facilities that study emerging infectious diseases and develop diagnostic tests, treatments, and vaccines to promote public health. BSL-4 research studies infectious diseases that are usually life-threatening and that have no available vaccine or therapy. There are 11 BSL-4 labs across North America—10 in the United States, and one in Winnipeg, Canada.
Original article from: BU Today posted on January 23, 2017. by Barbara Moran
In 2014, Ebola exploded across western Africa. It was the worst outbreak of the virus in recorded history, killing more than 11,000 people before it sputtered out in early 2016. In the Republic of Guinea, the epicenter of the epidemic, around 60 percent of people infected with Ebola died.
While the outbreak taught physicians and scientists much about Ebola, many questions remain. Foremost among them: why do some people survive an infection, while others die? Researchers know that some obvious factors, like supportive hospital care, improve prognosis. They also know that high viral load—the amount of virus present in the body—is frequently associated with death. But these factors alone didn’t account for all those who survived or succumbed to the disease, and they didn’t always predict who would live or die.
Now, a team of researchers led by Boston University, the University of Liverpool, Public Health England, and other international agencies has discovered a biomarker that can help predict the progression of the disease: a handful of genes that are overactivated in patients who succumb to the disease. These genes indicate an overly aggressive primary immune response, which can damage organs—particularly the liver—and paradoxically, may hamper a more targeted immune response. The research, funded by the United Kingdom’s National Institute for Health Research and the US Food and Drug Administration, and published on January 19, 2017, in the journal Genome Biology, suggests a new type of blood test that while still in the preliminary stages of development, might be useful in future outbreaks to steer patients to the best treatment.
“The study suggests that something about the way people respond to infection affects their chance of survival,” says John Connor, a School of Medicine associate professor of microbiology at BU’s National Emerging Infectious Diseases Laboratories and corresponding author on the study. “We can get a sense of who will survive and who won’t, and we can get it earlier,” he adds. “This is the first study of this type ever done on this scale.”
Original article from: Boston Globe posted on December 29, 2016. by Dante Ramos
For humanity to conquer Ebola and other deadly diseases, we need the right combination of scientists to study them from every possible angle. Where’s that more likely to happen — in a state-of-the-art biolab amid the world’s deepest pool of scientific and medical brainpower, or in a hypothetical facility on the dark side of the moon, where no scientist will ever want to work?
The answer is obvious. Which is why Boston University’s National Emerging Infectious Diseases Laboratories, located on Albany Street in Boston’s dense South End, should be allowed to host research even on so-called Biosafety Level 4 germs — microbes that cause life-threatening diseases for which there is no vaccine or treatment. Recently, the Centers for Disease Control and Prevention made just that judgment, giving the biolab a crucial approval.
Built with a $200 million federal grant awarded way back in 2003, the biolab building — which I’ve toured — is impressive, highly secure, and woefully underused. The decade-and-a-half-long battle over Level 4 research has hampered its ability to attract researchers.
The Boston Public Health Commission, in whose hands the facility’s future now lies, shouldn’t let misunderstandings about how scientists operate, and about how to keep people safest from dangerous germs, get in the way of life-saving research.
Original article from: Boston Globe posted on December 24, 2016. by Evan Allen & Felicia Gans
The Centers for Disease Control and Prevention has approved a Biosafety Level 4 laboratory to operate on Boston University’s medical campus in the South End, according to the Boston Public Health Commission.
Scientists in the National Emerging Infectious Diseases lab would have clearance to study the world’s deadliest pathogens, such as Ebola. The biolab still needs to win approval from the city’s health commission before that research can begin.
“It’s an important step; we’re excited that they have recognized the quality of our people and facilities, but we still need to wait on the rest of the process,” said Ronald B. Corley, the lab’s director.
The spread of Ebola and, more recently, the Zika virus, has shown how quickly pathogens can travel around the world, Corley said — and there are some we have not even discovered.
“This isn’t a closed circle. There are many pathogens out there that, as we encroach on the wilderness areas and forests, as we change the environment, we’re going to run into more and more,” Corley said. “Every little bit we learn helps us solve the problems for the next one.”
The Boston Public Health Commission said in a statement that it has been reviewing safety plans and procedures at the lab since 2013.
The commission “will continue to carry out a rigorous review process of National Emerging Infectious Diseases Laboratories’ application, including a review of safety and security protocols and an ongoing monitoring and inspection program to ensure that the Level 4 laboratory can operate safely prior to issuing any permits,” the commission said.